Rhelion Life Sciences Subsidiary to Speak at FDA Hearing on Psychedelic Drugs

Rhelion Life Sciences Corp., an Ontario-based company advancing innovation and research within the legal psychedelic sector, announced that its wholly owned subsidiary, Filament Health Corp., will deliver oral remarks at a United States Food and Drug Administration (FDA) public hearing on the potential future therapeutic use of psychedelic drugs. The hearing, held on September 14, 2026, aims to gather input on the development, evaluation, and potential future therapeutic use of psychedelic drugs.

Sarit Hashkes, President of Filament Health Corp., will speak at the hearing, which is being streamed live on the FDA's YouTube channel. The event is part of the FDA's Center for Drug Evaluation and Research's efforts to consider the future of psychedelic drug therapies. Filament is among the organizations providing oral remarks during the public comment period.

Rhelion Life Sciences Corp. CEO Todd Shapiro expressed gratitude for the opportunity to contribute to the dialogue.

PEX010, Filament's patented, standardized, Good Manufacturing Practice (GMP) manufactured botanical psilocybin drug candidate, is a key focus of the company's research. The drug candidate is produced using proprietary extraction, purification, and stabilization methods that ensure consistent composition across every dose, every study, and every research site. On April 30, 2026, Rhelion Life Sciences Corp. completed its acquisition of Filament Health Corp., including its portfolio of 77 issued patents across 13 patent families and its lead drug candidate, PEX010.

Rhelion Life Sciences Corp. is a science and research-led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.

The FDA public hearing is part of a broader effort to explore the potential therapeutic uses of psychedelic drugs. Filament Health Corp. will present its views on the development and evaluation of psychedelic drugs, contributing to the ongoing discourse on their potential applications in mental and behavioral health. The hearing is scheduled to take place virtually and in person, with Hashkes speaking around 3:40 PM Eastern Time.

The outcome of the hearing could have significant implications for the future of psychedelic drug research and therapy. Rhelion Life Sciences Corp. remains committed to advancing its research and contributing to the development of safe and effective psychedelic therapies.